PD-L1 Expression in Biliary Tract Cancer: Comparison Across Antibody Clones and Role as a Predictor of Response to Chemoimmunotherapy: A Meta-Analysis
- 1 May 2025
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400475
Abstract
PURPOSE: PD-L1 positivity in biliary tract cancers (BTCs) is reported from 4% to 76%. BTC clinical trials have not demonstrated PD-L1 expression as a predictor of response to chemotherapy combined with immune checkpoint inhibitor (chemo-ICI). This meta-analysis examines PD-L1 positivity rates in BTC and association between PD-L1 expression and outcomes in patients treated with chemo-ICI. Materials and Methods: Observational studies or clinical trials reporting tissue-based PD-L1 expression by Tumor Proportional Score/Combined Positive Score using immunohistochemistry were included. Clinical trials of BTC treated with chemo-ICI were included to assess PD-L1 expression on treatment response. PubMed, Embase, Web of Science, and Cochrane Library were searched for relevant studies before November 15, 2023. Methods of PD-L1 assessment, including antibody clone, cutoff for PD-L1 positivity, and anatomical subtype, were analyzed. Overall survival (OS) and objective response rates (ORRs) were the main outcomes. The generic inverse variance method and random-effect model were used to assess pooled effect sizes. RESULTS: Fifty-six studies met eligibility criteria. Among 7,768 patients, pooled PD-L1 positivity was 30%. Positivity rates varied significantly by antibody clone (5H1, 58% v SP142, 17%; P = .02). Clinical trials reported a higher positivity rate compared with observational studies (48% v 26%; P < .01). Across five phase I/II clinical trials (194 patients), PD-L1 ≥1% patients tended to have a better ORR than PD-L1 v 46%; P = .08). In two randomized controlled trials (874 patients), PD-L1 ≥1% had a statistically significant improvement in OS (hazard ratio [HR], 0.83; P < .01), while PD-L1 P = .2). CONCLUSION: Given the high PD-L1 positivity rate seen in this study, as well as a possible signal of predictive response for chemo-ICI treatment, PD-L1 expression should be further explored as a predictive biomarker.Keywords
This publication has 78 references indexed in Scilit:
- A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancerCancer Immunology, Immunotherapy, 2022
- Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trialEuropean Journal of Cancer, 2022
- The immunogenomic landscape of resected intrahepatic cholangiocarcinomaHepatology, 2021
- Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death‐Ligand 1 Blockade ResponsesHepatology, 2021
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract CancerJAMA Oncology, 2020
- Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinomaSurgery Today, 2020
- Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic CholangiocarcinomaDigestive Diseases and Sciences, 2019
- Global trends and predictions in hepatocellular carcinoma mortalityJournal of Hepatology, 2017
- Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English editionJournal of Hepato-Biliary-Pancreatic Sciences, 2015
- In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication biasJournal of Clinical Epidemiology, 2014